Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I

Chapuis AG1, Afanasiev OK2, Iyer JG3, Paulson KG2, Parvathaneni U4, Hwang JH5, Lai I1, Roberts IM1, Sloan HL1, Bhatia S6, Shibuya KC1, Gooley T1, Desmarais C7, Koelle DM8, Yee C1, Nghiem P2. 1Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA, 2Department of Pathology, University of Washington, Seattle, WA, USA ; Department of Medicine (Dermatology), University of Washington, Seattle, WA, USA, 3Department of Medicine (Dermatology), University of Washington, Seattle, WA, USA, 4Division of Radiation Oncology, UWMC, Seattle, WA, USA, 5Division of Gastroenterology, UWMC, Seattle, WA, USA, 6Department of Medicine (Medical Oncology), University of Washington, Seattle, WA, USA, 7Adaptive Biotechnologies, Seattle, WA, USA, 8Department of Medicine (Dermatology), University of Washington, Seattle, WA, USA ; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA ; Department of Global Health, University of Washington, Seattle, WA, USA ; Vaccine and Infectious Disease Division, FHCRC, Seattle, WA, USA ; Benaroya Research Institute, Seattle, WA, USA.